BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27775076)

  • 1. Multiplatform-based molecular subtypes of non-small-cell lung cancer.
    Chen F; Zhang Y; Parra E; Rodriguez J; Behrens C; Akbani R; Lu Y; Kurie JM; Gibbons DL; Mills GB; Wistuba II; Creighton CJ
    Oncogene; 2017 Mar; 36(10):1384-1393. PubMed ID: 27775076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
    Lockwood WW; Wilson IM; Coe BP; Chari R; Pikor LA; Thu KL; Solis LM; Nunez MI; Behrens C; Yee J; English J; Murray N; Tsao MS; Minna JD; Gazdar AF; Wistuba II; MacAulay CE; Lam S; Lam WL
    PLoS One; 2012; 7(5):e37775. PubMed ID: 22629454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer.
    Zhu J; Liu Y; Zhao M; Cao K; Ma J; Peng S
    Aging (Albany NY); 2021 Jan; 13(3):4482-4502. PubMed ID: 33495411
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non‑small cell lung cancer.
    Hu J; Shang Y; Shi X; Zhang S; Shi J; Yao M; Wang A; Shou T; Shi W; Wang K; Liu A; Pan X; Wang Y
    Oncol Rep; 2020 Jun; 43(6):2053-2061. PubMed ID: 32236597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancer.
    Han F; Chen S; Zhang K; Zhang K; Wang M; Wang P
    J Transl Med; 2024 Mar; 22(1):288. PubMed ID: 38493128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
    Aoki K; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Nishizawa T; Fukuda H; Ohashi K; Arai K; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Maruyama T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Mizuno H; Tsunoda H; Ochiai A
    Cancer Res Commun; 2023 Jun; 3(6):1026-1040. PubMed ID: 37377611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
    Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW
    Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
    Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
    Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment.
    Luo R; Ge C; Xiao X; Song J; Miao S; Tang Y; Lai J; Nian W; Song F; Ran L
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
    Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
    Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
    J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of prognostic signature of non-small cell lung cancer based on TCGA methylation data.
    Wang Y; Wang Y; Wang Y; Zhang Y
    Sci Rep; 2020 May; 10(1):8575. PubMed ID: 32444802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
    Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
    Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma.
    Qin N; Li Y; Wang C; Zhu M; Dai J; Hong T; Albanes D; Lam S; Tardon A; Chen C; Goodman G; Bojesen SE; Landi MT; Johansson M; Risch A; Wichmann HE; Bickeboller H; Rennert G; Arnold S; Brennan P; Field JK; Shete S; Le Marchand L; Melander O; Brunnstrom H; Liu G; Hung RJ; Andrew A; Kiemeney LA; Zienolddiny S; Grankvist K; Johansson M; Caporaso N; Woll P; Lazarus P; Schabath MB; Aldrich MC; Stevens VL; Jin G; Christiani DC; Hu Z; Amos CI; Ma H; Shen H
    Front Med; 2021 Apr; 15(2):275-291. PubMed ID: 32889700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
    Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
    FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rab11-FIP2 suppressed tumor growth via regulation of PGK1 ubiquitination in non-small cell lung cancer.
    Dong W; Li H; Wu X
    Biochem Biophys Res Commun; 2019 Jan; 508(1):60-65. PubMed ID: 30471866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.